Psychopharmacotherapy Market Insights

Obstacles & Opportunities in Mood Disorders & Cognitive Impairment, 2005-2012

Publication Date November 2005
ISBN n/a
Pages 91
Tables 22
Figures 6

Print £825 $1295

 Add to Basket

PDF £795 $1250

Single user

 Add to Basket

PDF £4600 $7215

Companywide user

 Add to Basket
Examines the global mood disorder sector and highlights the converging market stimulators and inhibitors that may lead to a market decline from an estimated US$17.4 billion in 2005 to US$15 billion in 2012

Examines the global mood disorder sector and highlights the converging market stimulators and inhibitors that may lead to a market decline from an estimated US$17.4 billion in 2005 to US$15 billion in 2012. Key factors discussed include patent expirations of leading antidepressants over the next 7 years, increased generic substitution trends, safety concerns over SSRIs; cost-containment in prescribing; and litigation activities between research-based and generic companies. Key market stimulators identified to buffer the decline include the introduction of new drug classes, new formulations, line extensions, increased patient populations, and treatment resistance. The report also evaluates the emerging market sector of cognitive and memory impairment and shows the extent of R&D activities within the field. Analysis of both sectors reveals candidates that have top-line earning prospects and also provides an insight into potential licensing or acquisition opportunities in promising psychopharmacotherapy market subsectors.


REPORT HIGHLIGHTS AND KEY FINDINGS
  • Pharmacotherapies indicated for mood disorders account for a market valued at US$17.4 billion, which is forecast to decrease 13.6% CAGR to US$15 billion by 2012
  • Critical analysis of depression, anxiety disorders, and cognitive and memory impairment
  • Review of epidemiological, aetiological, and therapeutic data for key therapy areas
  • Analysis of 10 marketed products and inclusion of 88 R&D candidates identified in preclinical to clinical stages of development for depressive illnesses and cognitive impairment
  • Sales estimates (US$) to 2012 for major therapy areas
  • Strategic insights for life-cycle optimization and product development
  • Critical evaluation of leading antidepressants
  • Emerging markets identified and sector analysis
  • Trend analysis of industry events and activities over past 2 years
  • Detailed R&D themes and clusters by therapy area
  • Data generation on sector and market values between 2004 and 2012 and therapy forecasts by 2020 (US$)
  • High revenue-yielding prospects identified with projected sales estimations
  • R&D pipeline positioning for key therapy areas
  • Market insights for product development and drug promotion

REASONS TO PURCHASE THIS REPORT
  • Detailed survey and analysis of the current and future mood disorder market
  • Comprehensive update on key marketed products indicated for depression and anxiety disorders
  • Review of epidemiological, demographic, aetiological, and therapeutic data associated with mood disorders and cognitive impairment
  • Market analysis and insight of key therapy areas and pipelines
  • Market value predictions of individual marketed products to 2012
  • Insight and trend analysis of pipeline products for depressive illnesses and cognitive and memory impairment
  • Review of promising pipeline products and potential market opportunities
  • Insight into potential blockbusters in the mood disorder and cognitive impairment therapy areas
  • Illustrates unmet needs of current pharmacotherapies to treat mood disorders and the underserved area of cognitive impairment
  • Provides extensive coverage of the R&D pipeline of key players in the depression/anxiety disorders and cognitive/memory impairments
  • Illustrates potential high-revenue earning prospects that are differentiated by novel indications or mechanism of action
  • Provides leads for potential licensing opportunities

COMPANIES MENTIONED IN REPORT
ABIOGEN, ABRIKA PHARMACEUTICALS, ALPHAPHARM, ALPHARMA, AMARIN, ANCHEN PHARMACEUTICALS, ANTARES PHARMA, APOTEX, ASTRAZENECA, BARR LABORATORIES, BENTLEY PHARMACEUTICALS, BIOVAIL, BOEHRINGER INGELHEIM, BRISTOL-MYERS SQUIBB, BTG, CARACO PHARMACEUTICAL, LABORATORIES, CEPHALON, CIMA LABS, CIPLA, COLLEGIUM PHARMACEUTICALS, CORTEX PHARMACEUTICALS, CYPRESS BIOSCIENCE, DOV, DR REDDY’S LABORATORIES, EON LABS, ENHANCE BIOTECH, FABRE-KRAMER PHARMACEUTICALS, FOREST LABORATORIES, GENAISSANCE PHARMACEUTICALS, GLAXOSMITHKLINE, HELICON THERAPEUTICS, HEXAL, IMPAX LABORATORIES, IPSEN, IVAX, JOHNSON & JOHNSON, LILLY, MERCK, MEMORY PHARMACEUTICALS, MYLAN LABORATORIES, NEUROCRINE, NEUROGEN, NEUROSEARCH, NEURO3D, NOVARTIS, ONO PHARMACEUTICALS, ORGANON, PENTECH PHARMACEUTICALS, PFIZER, PHARMACEUTICAL RESOURCES, PHARMOS, PHERIN PHARMACEUTICALS, PREDIX, PRESCIENT NEURO-PHARMA, ROCHE, SAEGIS PHARMACEUTICALS, SEPRACOR, SHIONOGI, SPECTRUM PHARMACEUTICALS, SYNTHON PHARMACEUTICALS, SANOFI-AVENTIS, SENTION PHARMA, SERVIER, SK PHARMA, SKYEPHARMA, SOLVAY PHARMACEUTICALS, SOMERSET PHARMACEUTICALS, TAISHO, TARGACEPT, TETRAGENEX, TEVA PHARMACEUTICAL, TORPHARM, LUNDBECK, UCB PHARMA, VANDA PHARMACEUTICALS, VELA PHARMACEUTICALS, WATSON PHARMACEUTICALS, WYETH.

Chapter 1 Introduction to Mood Disorders and Cognitive Impairment


Depression
Prevalence
Aetiology of Depression
Types of Depression
Major depression
Dysthymia
Bipolar Disorder
Symptoms of Depression
Anxiety Disorders
Prevalence

Cognitive Impairments and Memory Deficits
Prevalence
Pharmacotherapy for Cognitive Impairment

Chapter 2 The Global Market for Mood Disorders: Depression and Anxiety


Mood Disorders: Depression and Anxiety21 Market Overview of Drugs to Treat Depression and Anxiety Disorders
Market Analysis and Insights for Drugs to Treat Depressive Illnesses
Market Analysis: Antidepressant Therapy Area
Prozac (Fluoxetine) - Eli Lilly
Product Overview
Indications and Supplementary Labelling
Patent Expiry and Reformulation
Sales Prospects
Commercial Outlook
Cymbalta (Duloxetine) - Eli Lilly/Boehringer Ingelheim
Product Overview
Indications and Supplementary Labelling
Sales Prospects
Commercial Outlook
Zoloft/Lustral (Sertraline) - Pfizer
Product Overview
Indications and Supplementary Labelling
Patent Expiry and Reformulation
Sales Prospects
Commercial Outlook
Seroxat/Paxil/Deroxat (Paroxetine) - GlaxoSmithKline
Product Overview
Indications and Supplementary Labelling
Patent Expiry and Reformulation
Sales Prospects
Commercial Outlook
Wellbutrin (Bupropion) - GlaxoSmithKline
Product Overview
Indications and Supplementary Labelling
Patent Expiry and Reformulation
Sales Prospects
Commercial Outlook
Effexor (Venlafaxine) - Wyeth
Product Overview
Indications and Supplementary Labelling
Patent Expiry and Reformulation
Sales Prospects
Commercial Outlook
Remeron/Zispin (Mirtazapine) - Organon/Akzo Nobel
Product Overview
Indications and Supplementary Labelling
Patent Expiry and Reformulation
Sales Prospects
Commercial Outlook
Cipramil/Celexa (Citalopram) - Lundbeck/Forest Laboratories
Product Overview
Indications and Supplementary Labelling
Patent Expiry and Reformulation
Sales Prospects
Commercial Outlook
Cipralex/Lexapro (Escitalopram) - Lundbeck/Forest
Product Overview
Indications and Supplementary Labelling
Patent Expiry and Reformulation
Sales Prospects
Commercial Outlook
Future Considerations and Market Insights for the Antidepressant Market56 Pipeline Antidepressants
Pipeline Focus
Valdoxan (Agomelatine) - Servier

Pharmacotherapeutics for Cognitive Impairment and /Memory Deficits
Future Market Focus - Age-Related Cognitive Decline
Nootropil (Piracetam) - UCB Pharma
Companies Developing Drugs for Cognitive and Memory Impairment
EGb 761/Tanakan - Ipsen

Chapter 3 Drugs in Research and Development


Pipeline Mood Stabilizers and Drugs for Cognitive Impairment
Drugs in Development for Mood Disorders: Antidepressants and Anxiolytics
Depression and Anxiety: Research and Development Overview
Drugs in Development for Cognitive and Memory Impairment
Cognitive/Memory Impairment - Research and Development Overview

Chapter 4 Market Analysis, Therapy Forecasting, and Prospect Mining


Data Analysis, Therapy Forecasting, and Prospect Mining
Market Analysis and Therapy Forecasting
Antidepressants and Anxiolytics80 Therapy Area Forecasts

Comparative Analysis: Antidepressant/Anxiolytic Product Sales

Prospect Mining
Mood Disorders: Depression and Anxiety
Cognitive and Memory Impairment

Therapy Area Forecasts, 2012 and 2020

Chapter 5 Report Synopsis

Depressive/Anxiety and Cognitive/Memory Impairment - Key Data Points

Bibliography and Reference Sources

List of Tables


Table 1.1 Role of Neurotransmitters in Depression
Table 1.2 Symptoms of Depression and Bipolar Disorder/Mania
Table 1.3 Major Anxiety Disorders
Table 1.4 Causes of Dementia
Table 2.1 Estimated Global Sales & Forecasts of Leading Antidepressants, 2004-2012 (US$m) Table 2.2 Estimated Annual Growth Rates of Leading Antidepressants (%), 2004-
Table 2.3 Leading Antidepressants Ranked by Sales, 2005 & 2012 25 Table 2.4 Primary and Secondary Indications for Antidepressants26 Table 2.5 Estimated Sales (US$) and Annual Growth (%) of Prozac, 2005-2012
Table 2.6 Estimated Sales (US$) and Annual Growth (%) of Cymbalta, 2005-2012
Table 2.7 Estimated Sales (US$) and Annual Growth (%) of Zoloft, 2005-2012
Table 2.8 Estimated Sales (US$) and Annual Growth (%) of Seroxat/Paxil, 2005-2012
Table 2.9 Estimated Sales (US$) and Annual Growth (%) of Wellbutrin, 2005-2012
Table 2.10 Estimated Sales (US$) and Annual Growth (%) of Effexor, 2005-2012
Table 2.11 Estimated Sales (US$) and Annual Growth (%) of Remeron, 2005-2012
Table 2.12 Estimated Sales (US$) and Annual Growth (%) of Cipramil/Celexa, 2005-1250 Table 2.13 Estimated Sales (US$) and Annual Growth (%) of Cipralex/Lexapro, 2005-12
Table 2.14 Drugs in Development for Cognitive and Memory Impairment, 2005 (partial)65 Table 3.1 Drugs in Development for Depression and Anxiety, 2005
Table 3.2 Drugs in Development for Cognitive and Memory Impairment, 2005
Table 4.1 Global Drug Market for Antidepressants and Anxiolytics (US$m) 2004-2012
Table 4.2 Therapy Area Forecasts for the Global Mood Disorders and Cognitive
Impairment Market Sectors, 2012 and 2020

List of Figures


Figure 2.1 Estimated Global Sales of Leading Antidepressants, 2005 & 2012
Figure 2.2 Estimated Market Share of Leading Antidepressants, 2005 & 2012
Figure 4.1 Therapy Area Forecasts for Antidepressants and Anxiolytics, 2005 & 2012 (US$m)
Figure 4.2 Comparative Analysis of Leading Antidepressants and Anxiolytics 2004-2012
Figure 4.3 Key Antidepressant/Anxiolytic Prospects in the CNS Development Pipeline, 2005
Figure 4.4 Key Cognitive and Memory Impairment Prospects in the CNS Development Pipeline, 2005